# Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 Kilograms

> **NCT01164475** · PHASE4 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 61 (actual)

## Conditions studied

- Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** Granulocyte-colony stimulating factor (G-CSF)
- **DRUG:** Fixed Dose Plerixafor
- **DRUG:** Weight-Based Plerixafor

## Key facts

- **NCT ID:** NCT01164475
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2013-02
- **Final completion:** 2013-02
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2014-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01164475

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01164475, "Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 Kilograms". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT01164475. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*